Scripta Insights Raises $17M for AI-Powered Pharmacy Navigation

Scripta Insights Raises $17M for AI-Powered Pharmacy Navigation

What You Should Know: 

Scripta Insights, an AI-powered pharmacy navigation platform, has secured $17M in Series B funding led by Aquiline, a private investment firm specializing in financial services and technology. 

– The latest investment brings Scripta’s total funding to $42M and supports its mission to address the rising cost of prescription drugs in the United States.

Addressing the Prescription Drug Affordability Crisis

The cost of prescription drugs is a significant burden for many Americans, leading to medication non-adherence and adverse health outcomes. Scripta Insights aims to alleviate this burden by providing consumers with transparent information and personalized guidance on affordable medication options.

Scripta’s Innovative Solutions

Scripta offers two key solutions:

  • Rx Navigator: Empowers employees and their dependents to explore all their prescription options, including lower-cost alternatives, coupons, and pharmacy comparisons.
  • Rx Monitor: Provides plan sponsors with analytics and insights to monitor and manage their prescription drug benefit costs.

Strategic Partnerships and Growth

Scripta has partnered with leading benefits brokers and healthcare organizations to expand its reach and enhance its platform. The company’s solutions are trusted by a growing number of self-insured health plans and employers, ranging from small businesses to Fortune 500 companies.

“We are changing the way people shop for prescription drugs in America,” said Eric Levin, CEO, Scripta Insights. “That may sound like a bold statement, but in the last year alone we’ve generated 78,000 prescription switches that have resulted in $29M in prescription savings. We’re creating an America where access, affordability and adherence to necessary medicines are no longer barriers to positive health outcomes. There is no greater proof point than the fact that 93 percent of the drug switches driven by our clinical recommendations stay switched even after 12 months.”